Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Gossamer Bio, Inc. (GOSS) Market Cap & Valuation Ratios

Gossamer Bio, Inc. (GOSS) has a market cap of $4.7B and a price-to-sales ratio of 88.1, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GOSSGossamer Bio, Inc.Follow GOSS — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
4.7B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
3 Nov, in 10 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
GOSS4.7—86.3—-3.5%+32%-312%—
ORKA5.3———-1.9%——-28%
MIRM5.2—8.9—-4.4%+44%-135%-224%
PTCT5.1—3.418.9-0.8%-43%12%—
SRRK5.1———-5.9%——-568%
ERAS5.0———-1.9%——-97%
DFTX4.8———-3.5%——-92%
CRSP4.8—223.8—-7.8%-65%—-30%
TVTX4.7—8.5219.52.0%+77%-7%-8%
DNTH4.3———-3.6%-61%—-32%
EWTX4.3———-3.7%——-48%
Median of these 10—8.7119.2-3.6%-43%-7%-48%

; EV/Sales 86.3 vs. 8.7.

Growth vs. price

each dot a company · hover or tap for values

Gossamer Bio, Inc. — questions

What is Gossamer Bio, Inc.'s market cap?
$4.7B.
What is Gossamer Bio, Inc.'s price-to-sales ratio?
88.1.

Every figure on this page comes from Gossamer Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.